Gilead Sciences Inc (GILD)

[DewDiligence]

Viread and Truvada are going off-patent soon (they are already off-patent in certain countries), but GILD is replacing Truvada-based single-tablet regimens with STRs incorporating TAF in place of Viread.

I've questioned whether this approach will be commercially successful, i.e. whether third-party payers will cover expensive TAF-based regimens when cheap regimens based on generic Truvada are available. However, GILD appears to be highly confident of its business plan to switch patients to TAF, so I don't see GILD doing any tinkering in HIV in the near future.